Novo Nordisk’s next-generation weight-loss drug CagriSema
6 days ago · Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently approved medicine, Zepbound, but didn’t cleanly surpass it in late ...
Novo Nordisk A/S: CagriSema demonstrates superior weight
Dec 20, 2024 · This was achieved even though only 57% of patients reached the highest CagriSema dose,” said Martin Holst Lange, executive vice president for Development at Novo Nordisk.
What went wrong with Novo Nordisk’s CagriSema obesity drug trial
3 days ago · As a result, Novo’s shares plummeted by as much as 27%, reaching their lowest point since August 2023. Novo stated that when patients adhered to the CagriSema treatment, they achieved an average weight loss of 22.7% after 68 weeks, with 40.4% losing 25% or more. However, this was still below the company’s target.
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
6 days ago · Novo Nordisk on Friday revealed disappointing results in a late-stage trial for its experimental next-generation obesity drug CagriSema, wiping as much as $125 billion off its market value.
Novo’s next-gen obesity drug misses expectations in closely …
Dec 20, 2024 · In the trial, Novo enrolled 3,417 people with a body mass index greater than 30 or above 27 and with one weight-related health condition. Trial investigators randomized them to take cagrisema, semaglutide and a placebo, cagrilintide and a placebo, or two placebo drugs. The main objective was a comparison of cagrisema to the two placebos on ...
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema …
6 days ago · Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock. "We are ...
Novo Nordisk shares plunge 20% after disappointing trial results; …
6 days ago · Shares of Novo Nordisk plummeted roughly 20% on Friday. The fall comes after the Danish pharmaceutical giant reported results in a late-stage trial for its experimental CagriSema weight loss drug ...
Novo Nordisk shares tumble as data on weight-loss drug trial …
6 days ago · CagriSema helped patients lose an average of 22.7 per cent of their body weight in a late-stage trial, Novo Nordisk said on Friday, only marginally beating the results of Mounjaro, a rival ...
'A worst case scenario for Novo': Read the market reaction to CagriSema …
6 days ago · Novo Nordisk said on Friday its experimental next-generation obesity drug CagriSema helped overweight patients cut their weight by 22.7% in a late-stage trial, below the 25% it had expected ...
Novo Nordisk shares plunge after CagriSema obesity drug trial ...
6 days ago · The CagriSema trial showed the drug helped patients cut their weight by 22.7%, below the 25% Novo Nordisk had expected. Novo's shares fell as much as 27% after the results were announced, hitting their lowest since August 2023 in one of the biggest one-day wipeouts on record for a European company. They were down 20% at 1440 GMT.